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Michael R. Sargen1, Ole Hoffstad1 and David J. Margolis1
Anecdotal reports of children experiencing eczema flares during winter and summer months along with global
variation in eczema prevalence has fueled speculation that climate may modulate disease activity. The aim of this
study was to determine whether long-term weather patterns affect the severity and persistence of eczema
symptoms in children. We performed a prospective cohort study of US children (N¼ 5,595) enrolled in PEER
(Pediatric Eczema Elective Registry) between 2004 and 2012 to evaluate the effect of climate (daily temperature,
daily sun exposure, daily humidity) on the severity of eczema symptoms. Odds ratios (ORs) were calculated for
the patient-evaluated outcome of disease control. Multivariate logistic regression modeling adjusting for gender,
race, income, and topical medication use demonstrated that higher temperature (OR¼ 0.90, 95% confidence
interval (CI): 0.87–0.93, Po0.001) and increased sun exposure (OR¼ 0.93, 95% CI: 0.89–0.98, P¼ 0.009) were
associated with poorly controlled eczema. Higher humidity (OR¼ 0.90, 95% CI: 0.812–0.997, P¼ 0.04) was also
associated with poorly controlled disease, but the statistical significance of this association was lost in our
multivariate analysis (P¼ 0.44).
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INTRODUCTION
Eczema, otherwise known as atopic dermatitis, is a chronic,
recurring inflammatory condition that is associated with
severe itching and dryness of the skin. The pathogenesis of
disease is multifactorial, resulting from a combination of
genetic and environmental factors that predispose individuals
to a defective skin barrier and that trigger an abnormal
immune response when environmental antigens penetrate
the skin (Fergusson et al., 1982; Schultz Larsen, 1993;
Fennessy et al., 2000). One of the genetic factors thought to
play a key role in the development of eczema is the protein
filaggrin (FLG) that aligns keratin intermediate filaments in the
skin in order to prevent transepidermal water loss, which is a
characteristic clinical feature of eczema. Individuals with FLG-
null mutations are at an increased risk for developing disease.
There currently exists widespread variation in eczema
prevalence worldwide (Beasley, 1998; Leung and Bieber,
2003; Asher et al., 2006; Shaw et al., 2011; Williams, 2011).
Several studies have interpreted global variation in eczema
prevalence as a possible indication that climatic factors may
have some influence on disease susceptibility (Suarez-Varela
et al., 2008; Osborne et al., 2012; Silverberg et al., 2013).
Osborne et al. (2012) demonstrated that the prevalence of
disease among Australian children decreases in areas with
increased sun exposure and warmer temperatures that are
closer to the equator. Silverberg et al. (2013) found similar
findings in the United States, showing that the prevalence of
eczema is decreased in parts of the country where there is
higher sun exposure, humidity, and temperature.
The effect of climate on the severity and persistence of
eczema symptoms is also a clinically important question that
has not been previously examined in any large prospective
study. Many patients anecdotally report eczema flares
during certain seasons of the year, particularly during
winter and summer months, and flares in response to
weather effects such as sweating (Kramer et al., 2005;
Langan, 2009; Langan et al., 2009). In this study, we
analyze the effect of long-term weather patterns (tempe-
rature, humidity, and UVA/UVB sun exposure) on disease
severity or persistence in a prospective, national cohort of US
children with eczema.
RESULTS
Patient demographics
The PEER (Pediatric Eczema Elective Registry) cohort enrolled
5,595 children between November 2004 and April 2012, and
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enrollees were followed for an average of 2.9 person-years.
Study participants were enrolled from every region of the
continental United States, with a slight predominance of
females within the study cohort (53.3% female vs. 46.7%
male patients). The majority of patients had either good
(47.5%) or limited (37.6%) disease control at enrollment,
and children were drawn from a wide spectrum of socio-
economic backgrounds. A more detailed description of the
PEER cohort can be found in Table 1. Correlation between
the climate variables was generally weak (Pearson’s
coefficients o0.1), except for temperature and sun exposure,
which were moderately correlated (Pearson’s coefficient
¼ 0.5871, Po0.001).
Temperature
Logistic regression analysis revealed that higher temperatures
were associated with poorly controlled eczema. For
every 5 1F increase in temperature, the odds (odds ratio
(OR)¼ 0.85, 95% confidence interval (CI): 0.82–0.89,
Po0.001) of patients describing their disease as poorly
controlled increased by 15% (Table 2). This association
between temperature (OR¼0.90, 95% CI: 0.87–0.93,
Po0.001) and disease control was also statistically significant
after adjusting for potential confounders including race,
ethnicity, gender, annual household income, and the use of
topical medications (topical steroids, topical tacrolimus, and
topical pimecrolimus; Table 2).
Sun exposure
Increased daily sun exposure was also associated with
poorly controlled disease. The odds (OR¼0.89, 95% CI:
0.84–0.94, Po0.001) of poorly controlled eczema
grew by 11% for each 5% increase in sun exposure for our
study cohort (Table 2). The statistical significance of this
association (OR¼0.93, 95% CI: 0.89–0.98, P¼0.009) was
also maintained after adjusting for potential confounders in
our multivariate analysis (Table 2). In addition, higher
cumulative UVA (adjusted OR¼0.91, 95% CI: 0.87–0.95,
Po0.001) and UVB (adjusted OR¼ 0.88, 95% CI: 0.84–0.92,
Po0.001) exposure was associated with poorly controlled
disease (Table 2).
Humidity
Higher humidity was associated with poorly controlled
eczema. There was a 10% rise in the odds (OR¼0.90, 95%
CI: 0.81–1.00, P¼0.04) of poorly controlled disease for every
10% increase in humidity (Table 2). The statistical significance
of this association (OR¼ 0.93, 95% CI: 0.84–1.02, P¼0.14)
was lost in our multivariate analysis (Table 2).
Subgroup analysis
The odds of poorly controlled disease were increased for each
of the subgroups in regions of the country with higher
temperatures, increased sun exposure, and increased humid-
ity. The statistical significance (Po0.05) of these associations
was generally maintained after adjusting for potential con-
founders such as patient use of topical medications and
income (Supplementary Table S1 online).
Table 1. Demographic characteristics of children in
PEER (Pediatric Eczema Elective Registry) cohort at
enrollment
Demographic variable Number Percent of total cohort
Size of cohort 5,595 100.0
Mean age at enrollment, years (SD) 7.3 (4.1)
Median age at enrollment, years 6.3
Mean age of first rash, years (SD) 2.2 (3.0)
Total person-years of follow-up 16,360
Sex
Male 2,612 46.7
Female 2,982 53.3
Race/ethnicity1
Hispanic or Latino 555 9.9
Black 2,946 52.7
White 2,245 40.1
Native 76 1.4
Asian 242 4.3
Pacific 26 0.5
Disease control at enrollment2
Complete disease control 230 4.1
Good disease control 2,656 47.5
Limited disease control 2,103 37.6
Uncontrolled disease 594 10.6
Not reported 12 0.2
Average household income per year
$0–$24,999 2,253 40.3
$25,000–$49,999 909 16.2
$50,000–$74,999 492 8.8
$75,000–$99,999 296 5.3
$100,000 or more 360 6.4
Prefer not to answer 1,285 23.0
Geographic distribution3
New England 76 1.4
Middle Atlantic 401 7.2
East North Central 1,040 18.6
West North Central 286 5.1
South Atlantic 1,525 27.3
East South Central 1,251 22.4
West South Central 710 12.7
Mountain 115 2.1
Pacific 187 3.3
Unknown 4 0.1
1Percentages do not total 100% because study participants could check
more than one box for race/ethnicity.
2Study participants (or the parent of the child) were asked to describe the
severity of disease at the time of study enrollment. Surveyed individuals
were asked to consider the extent of skin involvement and the severity of
itching in the previous 6 months when evaluating their disease severity.
3The US census regions.
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FLG genotyping subgroup
A total of 416 children (50.7% of genotyped subcohort,
N¼ 820), who described themselves as white on their initial
enrollment form, submitted saliva samples for genotyping of
the four most common null alleles among Caucasians of
European ancestry. The genotyped subgroup of children
within the PEER cohort was geographically and socioecono-
mically diverse and saliva samples were collected from every
region of the country. Additional demographic information for
this subgroup, including allelic frequencies, is available in
Supplementary Table S2 online. For the subgroup of white
children who submitted saliva samples and were found to
Table 2. Univariate and multivariate logistic regression analyses for outcome of disease control
Unadjusted ORs Adjusted1 ORs
OR 95% CI P-value OR 95% CI P-value
Daily temperature2,3
Low Ref Ref Ref Ref Ref Ref
Medium versus low 0.65 0.57–0.74 o0.001 0.82 0.72–0.94 0.003
High versus low 0.57 0.49–0.67 o0.001 0.67 0.57–0.79 o0.001
Trend (for every 5 1F increase in temperature) 0.85 0.82–0.89 o0.001 0.9 0.87–0.93 o0.001
Percentage daily sun exposure2,3
Low Ref Ref Ref Ref Ref Ref
Medium versus low 0.85 0.74–0.98 0.03 1.02 0.88–1.19 0.79
High versus low 0.57 0.49–0.66 o0.001 0.7 0.61–0.81 o0.001
Trend (for every 5% increase in daily sun exposure) 0.89 0.84–0.94 o0.001 0.93 0.89–0.98 0.009
Cumulative annual UVA exposure 3,4
Low Ref Ref Ref Ref Ref Ref
Medium versus low 0.95 0.83–1.08 0.42 1.09 0.95–1.26 0.21
High versus low 0.65 0.56–0.76 o0.001 0.77 0.66–0.90 0.001
Trend (for every 40,000 kJ m 2 per day increase in cumulative
annual UVA exposure)
0.86 0.82–0.90 o0.001 0.91 0.87–0.95 o0.001
Cumulative annual UVB exposure 2,3
Low Ref Ref Ref Ref Ref Ref
Medium versus low 1.09 0.96–1.25 0.19 1.21 1.05–1.39 0.007
High versus low 0.55 0.47–0.64 o0.001 0.69 0.60–0.80 o0.001
Trend (for every 1,000 kJ m2 per day increase in cumulative annual
UVB exposure)
0.85 0.82–0.89 o0.001 0.88 0.84–0.92 o0.001
Daily humidity2,3
Low Ref Ref Ref Ref Ref Ref
Medium versus low 0.87 0.72–1.06 0.17 0.96 0.78–1.18 0.72
High versus low 0.6 0.41–0.88 0.009 0.67 0.46–0.97 0.034
Trend (for every 10% increase in daily humidity) 0.9 0.812–0.997 0.04 0.93 0.84–1.02 0.14
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference.
1ORs adjusted for medication use (topical steroids, topical tacrolimus, topical pimecrolimus), gender, race (white vs. non-white), and income.
2Daily values for temperature, percentage sun exposure, and humidity were recorded at 5,808 weather stations from across the United States between 1961
and 1990 to calculate 30-year mean daily values, which were used in our statistical analysis.
3Daily temperature tertiles: low (o55 1F, N¼ 2,111), medium (55.1–65 1F, N¼ 2,549), and high (465 1F, N¼ 911). Percentage daily sun exposure tertiles:
low (o55%, N¼ 1,471), medium (56–60%, N¼ 1,949), and high (460%, N¼ 2,127). Daily humidity tertiles: low (o65%, N¼400), medium
(66–75%, N¼5,032), and high (475%, N¼ 139). Cumulative annual UVA exposure tertiles: low (o309,940 kJ m2 per day, N¼ 1,428), medium
(309,941–368,660 kJ m2 per day, N¼ 2,717), and high (4368,660 kJ m 2 per day, N¼ 1,450). Cumulative annual UVB exposure tertiles: low
(o6,492 kJ m2 per day, N¼ 1,455), medium (6,493–8,820 kJ m2 per day, N¼2,472), and high (48,820 kJ m 2 per day, N¼ 1,668).
4Daily UVA and UVB measurements (kJ m2 per day) were recorded from three TOMS (Total Ozone Mapping Spectrometer) weather satellites from 1978 to
2000. These daily measurements were subsequently used to calculate mean cumulative annual UVA and UVB exposures for a given location. All
measurements have been corrected for cloud cover and ozone that filter UV radiation.
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have FLG-null alleles, their distribution in the United States
was not correlated with any of the climate variables (Pearson’s
coefficients o0.10, Po0.001).
DISCUSSION
We performed a large-scale, prospective, longitudinal cohort
study evaluating the effect of long-term weather patterns on
the severity of eczema symptoms in children. Our analysis
revealed that geographic areas with increased temperature,
sun exposure (total, UVA, and UVB), and humidity were
associated with poorly controlled disease.
Several cross-sectional studies have attempted to
elucidate the relationship between climate and eczema
symptoms. In a large Australian study, researchers found that
the prevalence of eczema decreases in areas with increased
sun exposure and warmer temperatures that are closer to the
equator (Osborne et al., 2012). In addition, Silverberg et al.
(2013) recently reported that the prevalence of eczema is
decreased in parts of the United States where there is
increased humidity, UV index, and temperature. Prevalence
studies are excellent for evaluating the burden of disease
within an area, but they are unable to provide information
regarding risk for a defined outcome following a particular
exposure.
Disease incidence or flares following an exposure are best
evaluated through a prospective analysis. Previous studies
examining the effect of weather on eczema symptoms have
been underpowered and of too short duration to effectively
answer this question. (Langan et al. (2006) recruited a cohort
of 25 Irish children to record their eczema symptoms for a
period of 28 days. At the end of the study, the authors found
that increased humidity and heat were associated with a
higher incidence of disease flares. However, Kramer et al.
(2005) found mixed results when studying the effects of
climate on eczema symptoms in a cohort of 39 German
children. The authors observed this cohort for several months
(March through September 1999) and each of the
children recorded daily itch scores and the extent of skin
involvement. Of the 39 children in the study, 21 had worse
symptoms during winter months, and the itch and
extent scores for this cohort were reduced with higher
temperatures. In contrast, of the 18 children with worse
symptoms during summer months, higher temperatures
were associated with more severe disease. The results
of the study by Kramer et al. (2005) suggest two different
phenotypes of eczema. Their finding that a subgroup of
children with eczema developed worsening symptoms
during summer months is consistent with the results in our
study. It is unclear why some children developed flares
of their disease more frequently during colder winter
months. However, the purpose of these small-scale
prospective studies was to determine the short-term effects
of weather on eczema symptoms, whereas our study is
focused on the effect that long-term weather patterns have
on disease activity.
The explanation for increased temperatures, humidity, and
sun exposure resulting in poorly controlled eczema is not
entirely clear. It is possible that warm and humid weather
leads to increased sweating, which has an irritant effect on the
skin (Langan et al., 2006; Langan et al., 2009). The irritation
mediated by the acidic pH of sweat may promote T helper
type 2 and type 17-mediated inflammation, which down-
regulates FLG expression (Patterson et al., 2000; Kubo et al.,
2012). Warm and humid weather also promotes the
evaporation of water on the skin surface, which may further
exacerbate skin dryness, a characteristic clinical feature of
eczema. It is also possible that temperature, humidity, and sun
exposure may affect the functioning of the skin barrier through
yet unknown mechanisms.
Limitations
The prevalence and type of FLG mutations varies considerably
by population and country (Palmer et al., 2006; Sandilands
et al., 2006; Barker et al., 2007; Sandilands et al., 2007;
Henderson et al., 2008; Rodriguez et al., 2009; van den Oord
and Sheikh, 2009; Chen et al., 2011; Irvine et al., 2011;
Brown et al., 2012). FLG mutations are associated with more
severe and persistence eczema symptoms. In our analysis, a
potential confounder would be the distribution of children
with FLG-null alleles in parts of the United States with warm,
humid, and high sun exposure climates. We performed a
secondary analysis evaluating for any correlation between our
climate variables and the location of children with FLG
mutations. The power of the subgroup analysis was limited
by a low overall submission rate (15% for the entire cohort,
N¼ 820) of saliva samples among the cohort participants. In
addition, our genetic screening test was only equipped to
detect mutations of the FLG locus that are most commonly
seen among whites of European ancestry. Therefore, we
limited our subgroup analysis to children who described
themselves as Caucasian (N¼416, 50.7%) on their initial
enrollment form. The subgroup of white children who
submitted saliva samples comprised 7.4% of the total PEER
cohort, and for this small geographically diverse subgroup, our
climate–outcome associations were independent of FLG gen-
otype. However, the limited number of saliva samples
prevents us from determining whether geographic clustering
of children with FLG mutations is functioning as a confounder
in our overall analysis.
The objective of this study was to identify associations
between long-term weather patterns and eczema severity.
Statistically significant ORs in our analysis do not prove
causality. A temporal analysis with local weather data at or
around the time each child completed their 6-month survey
would provide insights into the short-term effects that weather
has on eczema symptoms, but would not necessarily provide
information on the long-term impact that climate has on
disease activity, which is the focus of our particular study.
Both questions are equally important and should be evaluated
in follow-up studies. It is also important to point out that
weather may be serving as a proxy for other environmental
factors that can exacerbate eczema symptoms. Previous
studies have shown that sweating, diet, water hardness, and
pollen exposure are each associated with eczema flares
(McNally et al., 1998; Reekers et al., 1999; Kramer et al.,
2005; Langan et al., 2009). Each of these external factors is
MR Sargen et al.
The Effect of Climate on Eczema Symptoms
54 Journal of Investigative Dermatology (2014), Volume 134
influenced by climate. Warmer temperatures also result in
earlier and greater overall seasonal production of tree (spring),
grass (summer), and ragweed (fall) pollen, which can trigger
eczema flares (Ziska and Beggs, 2012).
Future studies may also want to evaluate climate data for
the specific time interval of the cohort study. However,
weather patterns in the United States have been relatively
stable over the past century and climate data for the period of
2004–2012 is unlikely to change the findings in our analysis.
Finally, all patients in the PEER cohort used pimecrolimus
before the start of the study, and this medication is approved
by the Food and Drug (FDA) Administration for mild-to-
moderate eczema. Therefore, the effect of long-term weather
patterns on eczema severity may not be generalizable to
children with severe eczema. However, 37.6% and 10.6%,
respectively, of the children reported limited disease control or
uncontrolled disease at enrollment, suggesting that many
children within the PEER cohort suffered from moderate-to-
severe eczema. Therefore, our results may also be applicable
to children with severe disease.
Conclusions
We present data from a geographically diverse longitudinal
prospective analysis examining the effect of long-term weather
patterns on symptom severity in children with eczema. The
results of this study demonstrate that warm, humid, and high
sun exposure climates are associated with poorly controlled
disease.
MATERIALS AND METHODS
Study cohort
The study population included childreno18 years of age enrolled in
the PEER cohort, which is an ongoing prospective longitudinal
postmarketing safety analysis that was initiated in 2004 to evaluate
whether topical pimecrolimus is associated with systemic or cuta-
neous malignancies. All children were required to have parental
consent and a physician (dermatologist, pediatrician, allergist, pri-
mary care physician) diagnosis of eczema before enrollment. Accord-
ing to the FDA-approved protocol, each study participant was also
required to have a treatment history of either 6 continuous weeks of
topical 1% pimecrolimus or 6 total weeks of intermittent drug
exposure within the 6 months preceding enrollment. However, once
enrolled in the study, the treating physician was not expected to
continue treatment with pimecrolimus if other medications were
determined to be more appropriate for the child’s clinical symptoms.
Children were excluded from the PEER cohort if they had a history of
lymphoproliferative disease, systemic malignancy, cutaneous malig-
nancy, or had used systemic immunosuppressive medications such as
cyclosporine, tacrolimus, or methotrexate in the past. Each child in
conjunction with their parent or legal guardian completed an initial
enrollment form describing their baseline eczema symptoms. Indivi-
duals subsequently completed a follow-up survey every 6 months
evaluating their disease severity and describing their use of topical
medications. Informed written consent was obtained from each of the
study participants and our research protocol was approved by the
institutional review board at the Hospital of the University of
Pennsylvania in accordance with the Declaration of Helsinki Princi-
ples for medical research.
Outcome of interest
Our outcome of interest was disease control. Patients were asked to
qualitatively evaluate the severity of their eczema symptoms every 6
months. PEER children were given four options to describe their
disease: complete disease control, good disease control, limited disease
control, or uncontrolled disease. We dichotomized this outcome into a
‘‘well-controlled disease’’ category, which included patients who
responded with one of the first two options, and a ‘‘poorly controlled
disease’’ category for individuals who responded with one of the latter
two choices. In evaluating their disease, children and their parents
were asked to consider the extent of skin involvement and the
severity of symptoms such as itching. The patient self-described
outcome of disease control is a well-validated measure of eczema
severity that correlates with the EASI (Eczema Area and Severity
Index) scores (Hanifin et al., 2001; Eichenfield et al., 2002;
Housman et al., 2002; Kapp et al., 2002; Wahn et al., 2002;
Barbier et al., 2004; Schmitt et al., 2007; Kapoor et al.,
2008, 2009; van Velsen et al., 2010).
Covariates
The initial enrollment questionnaire contained 39 questions with
462 variables including information on gender, US census categories
for race/ethnicity (white, black or African American, Asian,
American Indian or Alaskan Native, Hawaiian or other Pacific
Islander, Hispanic or Latino), annual household income, and baseline
eczema symptoms. Study participants also completed a follow-up
questionnaire every 6 months with 24 questions evaluating disease
control and the use of topical medications in the previous 6 months
(topical pimecrolimus, topical tacrolimus, and topical corticoster-
oids). Survey questions addressing disease severity were modeled
after the UK Working Party’s Diagnostic Criteria for Atopic Dermatitis
and the ISAAC (International Study of Asthma and Allergies in
Childhood) questionnaire, which is freely available online (http://
isaac.auckland.ac.nz/).
Climate data
Data for temperature, sun exposure, and humidity were down-
loaded from the NCDC (National Climatic Data Center), which is
funded by the US NOAA (National Oceanic and Atmospheric
Administration): (http://hurricane.ncdc.noaa.gov/cgi-bin/climaps/
climaps.pl?directive=quick_results&subrnum=&pop=YES). Tem-
perature and humidity values were measured directly, whereas
sun exposure was reported as the percentage of daylight hours in
which sunshine was observed for a particular day. Daily values
for each variable were recorded at 5,808 weather stations from
across the United States between 1961 and 1990 to calculate 30-
year mean daily values, which were used in our statistical
analysis. This was the most comprehensive climate data that were
available at the time of our study and weather patterns in the
United States have been relatively stable over the past century
with less than a 1 to 2 1F change in most parts of the country
(http://www.epa.gov/climatechange/pdfs/print_temperature-
2012.pdf). UVA and UVB data were downloaded from the UCAR
(University Corporation for Atmospheric Research) website (Lee-
Taylor, 2007). Daily UVA and UVB measurements (kJ m 2 per
day) were recorded from three TOMS (Total Ozone Mapping
Spectrometer) weather satellites between 1978 and 2000. These
daily measurements were subsequently used to calculate mean
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annual cumulative UVA and UVB exposures at a given location,
which were used in our analysis. All measurements were
corrected for cloud cover and ozone that filter UV radiation.
The climate data were subsequently matched to each patient via
their geographic location (as determined by latitude and
longitude) using a kriging data interpolation algorithm in the
mapping program ArcGis 10.1 (ESRI, Redlands, CA).
Statistical analysis
The objective of this study was to identify associations between long-
term weather patterns and eczema severity. Patients were enrolled in
the PEER registry from all across the United States beginning in
November 2004. For this study, we included patients who were being
enrolled in PEER up to April 2012. We performed univariate and
multivariate GLLAMM (Generalized Linear Latent and Mixed Models)
logistic regression modeling for each climate variable in the statistical
program STATA 12.1 (StataCorp LP, College Station, TX) to evaluate
for changes in disease control for each patient over time. Our ORs
reflect the odds of well-controlled disease with increasing tempera-
ture, sun exposure (total, UVA, and UVB), and humidity. Patients
were grouped for each climate variable into ranges of approximately
equal intervals (e.g., 5 1F for temperature, 5% for sun exposure, and
10% for humidity) in order to calculate the change in odds for every
interval change in a particular climate variable. Patients were also
grouped into approximate tertiles for comparison, which is an
accepted methodology for evaluating dichotomized outcomes when
there is an exposure with continuous variation (Arkema et al., 2013).
The tertiles are composed of unequal numbers of children because
the geographic distribution of children along the spectrum of
temperature, sun exposure, and humidity climates in the United
States was nonuniform (Table 1). The cut-off points for each tertile
were created to ensure that each group was sufficiently powered to
detect associations between weather exposure and disease severity.
In our multivariate analysis, we adjusted for race, ethnicity, gender,
annual household income, and topical medication use (topical
tacrolimus, topical pimecrolimus, topical corticosteroids).
Subgroup analyses
We performed univariate and multivariate logistic regression analyses
for the following self-designated subgroups: white, non-white, males,
and females. All patients in the PEER cohort were also asked to submit
saliva samples for FLG genotyping (Margolis et al., 2011). DNA self-
collection kits (DNA Genotek, Kanata, ON, Canada) were used to
collect all specimens. The FLG locus was genotyped for the four most
common null alleles among whites of European ancestry (R501X,
2282del14, R2447X, and S3247X) using custom-made TaqMan
allelic discrimination assays (Applied Biosystems, Foster City, CA)
according to previously published protocols (Smith et al., 2006;
Sandilands et al., 2007). Additional details of our genetic analysis
have been previously published elsewhere (Margolis et al., 2011;
Margolis et al., 2012). Pearson’s coefficients were calculated for each
of the climate variables to determine if they were correlated with the
distribution of white children with FLG mutations, which is a
potential confounder in our primary analysis (Margolis et al., 2012).
As was previously stated, the FLG locus was genotyped for the four
most common null alleles among whites of European ancestry
(R501X, 2282del14, R2447X, and S3247X). Therefore, non-white
children who submitted saliva samples (N¼ 404) may harbor a FLG
mutation that was not tested for in our screen. In contrast, a negative
mutation screen in white children likely represents a true negative as
the majority of these children are of European descent. As a result of
the unknown sensitivity of genetic testing for non-white children,
only the genetic results of Caucasian children were included in our
subgroup analysis.
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